EGFR Lung Cancer Resisters https://validator.w3.org/feed/docs/rss2.html NCCN Releases NSCLC Guideline Update, Dato-DXd Designated as a Preferred Second-Line Regimen in EGFR-Mutated Disease Lung Cancer in Nonsmoking Individuals Early Data Suggest Primary Tumor Resection Following EGFR TKI Treatment May Help Delay Disease Progression in Metastatic NSCLC The Power of Community: Jill Feldman Shares Advice for Getting Involved in Lung Cancer Advocacy The New Face of Lung Cancer: A Conversation with Two Young Lung Cancer Warriors New EGFR Resisters/LUNGevity Research Project Funded: Local CAR T as a Novel Therapeutic Strategy for CNS Progression in NSCLC Inaugural EGFR Resisters Patient and Caregiver Summit Was Awesome! SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025 NorthStar: LCT Plus Osimertinib Boosts PFS in Metastatic EGFR+ NSCLC Zipalertinib Shows Early Efficacy With Manageable Safety in EGFR-Mutant NSCLC With CNS or Leptomeningeal Disease Second-Line Sacituzumab Tirumotecan Displays PFS Benefit in EGFR+ NSCLC ESMO 2025: Latest in EGFR mutant NSCLC Phase II study of lazertinib and pemetrexed in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and leptomeningeal metastases: The KCSG LU 21-01, LAZARUS study BlossomHill Therapeutics Presents Preliminary Findings from Phase 1/2 SOLARA Trial of BH-30643 When EGFR+ Lung Cancer Spreads to the Brain Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial Prognostic implications of uncommon EGFR exon 19 deletion-insertion mutations in NSCLC treated with third-generation EGFR-TKIs Newsletter Archives WCLC 2025 Highlights: FLAURA2, HARMONi, ALCHEMIST with Dr. Balazs Halmos Membership 2026 EGFR Resisters Patient and Caregiver Summit – Sponsors Monthly Newsletters FDA Approval of Datopotamab deruxtecan (Dato-DXd) in EGFR Mutated Lung Cancer Aumolertinib Plus Chemo Shows Modest PFS Gain Over Monotherapy for EGFR/TSG-Mutant NSCLC AstraZeneca’s 2025 Global Lung Cancer Advocacy Exchange “Milestone” in EGFR-Positive NSCLC: The Importance of Options for Patient-Centered Care How to Read & Write Conference Abstracts FDA Grants Fast Track Designation to AVZO-1418/DB-1418 for EGFR+, TKI-Pretreated NSCLC Histological transformation in lung cancer: Mechanisms, clinical characteristics, and therapeutic approaches Highlights From ASCO 2025: Treatment Regimens for EGFR-Mutated Advanced NSCLC FDA Grants Accelerated Approval to Zongertinib for Nonsquamous NSCLC With HER2 TKD Mutations BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature ADC-, Bispecific Antibody–Based Therapies Help Build a New Treatment Paradigm in EGFR+ NSCLC Frontline Iza-Bren Plus Osimertinib Elicits 100% ORR in EGFR-Mutant NSCLC Tribute to Bonnie Addario 2026 EGFR Resisters Patient and Caregiver Summit accessibility The Phase 3 HARMONi Trial: Dr. Le Shares Insights at IASLC WCLC “What I Tell My Patients:” Making Sense of New Treatment Options in EGFR-positive NSCLC WCLC 2025 Highlights: FLAURA2 trial Local cranial radiation combined with third-generation tyrosine kinase inhibitors improve leptomeningeal metastasis disease-free survival in patients with EGFR-mutated non-small cell lung cancer and brain metastasis COMPEL Study Shows Continuing Osimertinib Treatment Through Progression with the Addition of Chemotherapy Improves Progression-Free Survival in EGFR-Mutated NSCLC American Cancer Society Lung Cancer Roundtable Webinars FDA Grants Breakthrough Therapy Designation to Izalontamab Brengitecan in EGFR+ NSCLC Contact Us Leadership EGFR Resisters Patient & Caregiver Summit Support Home